Abstract:Cellular senescence is a state of permanent cell-cycle arrest. Early in life, senescence has a physiologic role in tumor suppression and wound healing. However, gradually, as these senescent cells accumulate over the lifespan of an organism, they contribute to inflammation and the progression of age-related diseases, including neurodegeneration. Targeting senescent cells using a class of drugs known as "senolytics" holds great promise for the management of Alzheimer's and Parkinson's disease. Already, several senolytic compounds have been shown to ameliorate cognitive deficits across several preclinical models of neurodegeneration. Most of these senolytics (e.g., dasatinib) are repurposed clinical or experimental anticancer drugs, which trigger apoptosis of senescent cells by interfering with pro-survival pathways. However, outside of their senolytic function, many first-generation senolytics also have other less appreciated neuroprotective effects, such as potent antioxidant and anti-inflammatory activity. In addition, some senolytic drugs may also have negative dose-limiting toxicities, including thrombocytopenia. In this review, we discuss the various biologic pathways targeted by the leading senolytic drugs, namely dasatinib, quercetin, fisetin, and navitoclax. We further evaluate the clinical transability of these compounds for neurodegeneration, assessing their adverse effects, pharmacokinetic properties, and chemical structure. SIGNIFICANCE STATEMENT Currently, there are no effective disease-modifying treatments for the most prevalent neurodegenerative disorders, including Alzheimer's and Parkinson's disease. Some of the drugs currently available for treating these diseases are associated with unwanted side-effects and/or become less efficacious with time. Therefore, researchers have begun to explore new innovative treatments for these belligerent diseases, including senolytic drugs. These agents lead to the apoptosis of senescent cells thereby preventing their deleterious role in neurodegeneration.

Targeting mitochondrial dysfunction to salvage cellular senescence for managing neurodegeneration

Mitophagy: A promising therapeutic target for neuroprotection during ageing and age-related diseases

Targeting the Mitochondrial Permeability Transition Pore to Prevent Age-Associated Cell Damage and Neurodegeneration

Mitophagy regulation in aging and neurodegenerative disease

Signaling Pathways Concerning Mitochondrial Dysfunction: Implications in Neurodegeneration and Possible Molecular Targets

The Potential of Mitochondrial Therapeutics in the Treatment of Oxidative Stress and Inflammation in Aging

Exploring Mitochondrial Quality in Aging and Neurodegenerative Diseases

Targeting Mitochondria as a Strategy to Inhibit Cellular Senescence

Targeting Mitochondrial Dysfunction and Reactive Oxygen Species for Neurodegenerative Disease Treatment

Mitochondrial Function in Ageing: Coordination with Signalling and Transcriptional Pathways.

Pharmacological Targeting of Senescence with Senolytics as a New Therapeutic Strategy for Neurodegeneration

Modulation of Mitochondrial Function in Elderly Brain: Involvement of Autophagy and Apoptosis

Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View

Mitophagy, Diseases, and Aging

Targeting Mitochondrial Oxidative Stress as a Strategy to Treat Aging and Age-Related Diseases

Targeting the microbiota-mitochondria crosstalk in neurodegeneration with senotherapeutics

Modulation of Mitochondrial Function as a Therapeutic Strategy for Neurodegenerative Diseases

Therapeutic Targeting of Mitochondria-Proteostasis Axis by Antioxidant Polysaccharides in Neurodegeneration.

Mitostasis in age-associated neurodegeneration

Mitochondrial dysfunction and its association with age-related disorders

Alleviating Neurodegenerative Diseases Associated with Mitochondrial Defects by Therapeutic Biomolecules